Dissecting the VEGFC–Macrophage Axis in NASH-Associated Hepatic Fibrosis

Study Background and Research Question

Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by steatosis, inflammation, and fibrosis. It represents a severe phenotype within the spectrum of non-alcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated fatty liver disease (MAFLD), and is a leading cause of cirrhosis and liver-related morbidity worldwide. While the role of immune cell infiltration and fibrogenic signaling in NASH is well recognized, the contribution of vascular endothelial growth factor C (VEGFC) signaling—particularly in mediating hepatocyte-macrophage crosstalk—remains less understood. The reference study (Li et al., 2026) seeks to clarify whether and how downregulation of VEGFC contributes to the anti-fibrotic effects of naringin, a flavonoid with known hepatoprotective properties, in a clinically relevant NASH model.

Key Innovation from the Reference Study

The pivotal innovation in this work is the mechanistic dissection of the VEGFC–macrophage regulatory axis in the context of NASH-induced hepatic fibrosis. By integrating pharmacological inhibition (using the selective VEGFR-3 inhibitor SAR131675), genetic ablation (hepatocyte-specific Vegfc knockout), and clinical correlative studies, the authors establish a direct link between hepatocyte-derived VEGFC and the recruitment and phenotypic polarization of hepatic macrophages. This axis is shown to be a critical driver of fibrogenesis, offering a discrete molecular target for anti-fibrotic intervention beyond the canonical pathways of hepatic stellate cell activation.

Methods and Experimental Design Insights

The study employs a multifaceted approach:

• In vivo NASH model: Mice are fed a high-fat diet (HFD) for 24 weeks to induce steatohepatitis and fibrosis. Interventions with naringin (low and high doses) or SAR131675 commence at week 9 and continue for 16 weeks, modeling both prevention and reversal of disease progression.
• Genetic validation: Hepatocyte-specific Vegfc knockout (Vegfc^Hep-cKO) mice are generated to confirm the cell-autonomous role of hepatic VEGFC.
• Clinical translation: Serum VEGFC levels are measured in a hospital cohort (n=165), and public transcriptomic datasets (GSE162694, GSE130970) are analyzed for hepatic VEGFC expression in NAFLD/NASH patients.
• In vitro mechanistic studies: AML12 hepatocytes are manipulated (oleic acid challenge, recombinant VEGFC, or Vegfc knockdown/overexpression), and conditioned media are used to assay bone marrow-derived macrophage (BMDM) migration and polarization.

Pharmacological inhibition with SAR131675 is performed at a dose of 30 mg/kg/day, consistent with its validated preclinical anti-lymphangiogenic and anti-angiogenic activity (SAR131675 resource).

Core Findings and Why They Matter

The study yields several convergent lines of evidence:

• Naringin and SAR131675 both attenuate hepatic inflammation and fibrosis in the HFD model, with marked reductions in serum markers (ALT, AST), fibrotic gene expression (ACTA2, COL1A1), and histopathological scores.
• VEGFC expression is upregulated in NASH both in the animal model and in clinical samples; its downregulation by naringin or genetic knockout correlates with improved liver pathology.
• Inhibition of VEGFR-3 signaling reduces Ly6C^high monocyte/macrophage infiltration and promotes a shift toward the Ly6C^low reparative phenotype, implicating VEGFC as a key chemotactic and phenotypic regulator.
• Mechanistically, hepatocyte-derived VEGFC stimulates macrophage migration via VEGFR-3 and the CCL2/CCR2 axis, while also suppressing anti-inflammatory polarization by modulating IL-10 and CX3CR1 expression. Naringin disrupts this axis by reducing hepatic VEGFC production.

These results provide strong evidence that targeting the VEGFC–macrophage circuit can ameliorate fibrotic progression in NASH, and that both pharmacological VEGFR-3 inhibition and dietary flavonoids like naringin exert their benefit through this pathway (reference study).

Comparison with Existing Internal Articles

Recent internal reviews, such as Dissecting VEGFR-3: SAR131675 in Translational Fibrosis & Cancer, reinforce the translational value of SAR131675 as an anti-lymphangiogenic and anti-angiogenic compound in both cancer and fibrotic disease models. These sources highlight SAR131675’s high selectivity and robust in vivo efficacy, echoing its utility in delineating VEGFR-3–dependent disease mechanisms. The current reference study extends this paradigm to metabolic liver disease, evidencing the anti-fibrotic potential of VEGFR-3 inhibition via disruption of immune cell crosstalk rather than solely endothelial mechanisms. Additionally, Precision Inhibition of VEGFR-3: Mechanistic Insights discusses protocol optimization and the maturity of SAR131675 as a preclinical probe, advising careful consideration of metabolic liabilities observed in late-stage studies.

Protocol Parameters

• SAR131675 dosing: 30 mg/kg/day by oral gavage for 16 weeks, initiated at week 9 of HFD feeding to model advanced-stage NASH and fibrosis (reference study).
• Naringin dosing: 25 or 50 mg/kg/day by oral gavage, administered on the same schedule for comparative analysis.
• Genetic model: Induce hepatocyte-specific Vegfc knockout by crossing Vegfc^flox/flox with Alb-CreERT2 mice; tamoxifen induction as per standard protocols.
• In vitro stimulation: Treat AML12 hepatocytes with 0.5 mM oleic acid or 100 ng/mL recombinant VEGFC for 24 hours; conditioned media applied to BMDMs to assess migration and phenotypic transition.

These parameters are literature-backed and can guide experimental replication or adaptation in related workflows.

Limitations and Transferability

While the study offers compelling evidence for VEGFC–VEGFR-3 signaling as a fibrogenic driver in NASH, several caveats merit consideration. First, the primary data derive from a murine model and selected human cohorts, necessitating validation in broader clinical settings. The long-term safety of VEGFR-3 inhibition remains unresolved; SAR131675 development was discontinued due to adverse metabolic effects in preclinical studies (SAR131675 resource). Thus, while the anti-lymphangiogenic and anti-angiogenic mechanisms are robust, translational maturity for chronic metabolic disease remains limited. Additionally, the study focuses on advanced-stage NASH; applicability to early disease or other fibrotic organs is not established by this dataset.

Why this cross-domain matters, maturity, and limitations

Bridging lymphangiogenic and immune pathways in metabolic liver disease offers a novel perspective on NASH pathogenesis. Historically, VEGFR-3 inhibitors such as SAR131675 have been deployed mainly in oncology and classic fibrotic models (SAR131675: Mechanistic Insights and Strategic Horizons). The current evidence underscores the relevance of anti-lymphangiogenic agents in modulating immune cell trafficking and inflammation in metabolic contexts. However, limitations in cross-species translation and the compound’s discontinued status for clinical use highlight the need for careful experimental design and critical interpretation of long-term metabolic effects.

Research Support Resources

For researchers seeking to recapitulate or extend these findings, SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301), is available for preclinical workflows focused on VEGFR-3 signaling, lymphangiogenesis, and immune modulation. Its use should be guided by published protocol parameters and awareness of its selectivity and metabolic profile. Additional mechanistic insights and workflow recommendations can be found in recent method-focused reviews (see here).